Production of a mouse monoclonal IgM antibody that targets the carbohydrate Thomsen-nouveau cancer antigen resulting in in vivo and in vitro tumor killing

Cancer Immunology, Immunotherapy : CII
Kevin R TrabbicPeter R Andreana

Abstract

The construction of a tumor-associated carbohydrate antigen-zwitterionic polysaccharide conjugate, Thomsen-nouveau-polysaccharide A1 (Tn-PS A1, where Tn = D-GalpNAc), has led to the development of a carbohydrate binding monoclonal antibody named Kt-IgM-8. Kt-IgM-8 was produced via hybridoma from Tn-PS A1 hyperimmunized Jackson Laboratory C57BL/6 mice, splenocytes and the murine myeloma cell line Sp2/0Ag14 with subsequent cloning on methyl cellulose semi-solid media. This in-house generated monoclonal antibody negates binding influenced from peptides, proteins, and lipids and preferentially binds monovalent Tn antigen as noted by ELISA, FACS, and glycan array technologies. Kt-IgM-8 demonstrated in vitro and in vivo tumor killing against the Michigan Cancer Foundation breast cell line 7 (MCF-7). In vitro tumor killing was observed using an LDH assay that measured antibody-induced complement-dependent cytotoxicity and these results were validated in an in vivo passive immunotherapy approach using an MCF-7 cell line-derived xenograft model. Kt-IgM-8 is effective in killing tumor cells at 30% cytotoxicity, and furthermore, it demonstrated approximately 40% reduction in tumor growth in the MCF-7 model.

References

Mar 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·H NakadaI Yamashina
Mar 15, 2001·Proceedings of the National Academy of Sciences of the United States of America·V KudryashovK O Lloyd
Mar 15, 2001·Proceedings of the National Academy of Sciences of the United States of America·T GilewskiS J Danishefsky
Dec 1, 2001·Expert Opinion on Biological Therapy·L A Holmberg, B M Sandmaier
Mar 7, 2003·Clinical Breast Cancer·Nuhad K Ibrahim, James Lee Murray
Oct 18, 2003·Cancer Immunology, Immunotherapy : CII·Reiko F IrieDonald L Morton
Apr 25, 2008·Current Protocols in Immunology·S M AndrewA Amin
Aug 21, 2008·Angewandte Chemie·Jeet Kalia, Ronald T Raines
Sep 2, 2008·Biological & Pharmaceutical Bulletin·Hiroshi AndoSo Ohta
Dec 20, 2008·Expert Review of Vaccines·Gloria C KooRichard J O'Reilly
Mar 12, 2009·Methods in Molecular Biology·Jamie Heimburg-Molinaro, Kate Rittenhouse-Olson
Apr 16, 2009·Journal of Proteome Research·Oyindasola OyelaranJeffrey C Gildersleeve
Jun 26, 2009·Journal of the American Chemical Society·Ravindra A De SilvaPeter R Andreana
Aug 27, 2009·Proceedings of the National Academy of Sciences of the United States of America·Daniel M Czajkowsky, Zhifeng Shao
Sep 3, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Martin A CheeverLynn M Matrisian
Oct 16, 2010·Nature Reviews. Immunology·Michael R Ehrenstein, Clare A Notley
Apr 8, 2011·Glycobiology·Charlotte WelinderBo Jansson
Feb 3, 2012·Cancer Immunology, Immunotherapy : CII·Ravindra A De SilvaPeter R Andreana
Jan 22, 2013·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Jan 11, 2014·Nature Biotechnology·Rob Saurabh Aggarwal
Dec 31, 2014·Proceedings of the National Academy of Sciences of the United States of America·Annie N SamrajAjit Varki
Feb 24, 2015·Molecular Immunology·Joost P M MelisPaul W H I Parren
May 6, 2015·Drugs·Sohita Dhillon
May 23, 2015·Nature Reviews. Cancer·George J Weiner
Nov 3, 2016·Journal of the American Chemical Society·Mengchao ShiPeter R Andreana
Oct 21, 2016·International Journal of Immunopathology and Pharmacology·Hye-Youn SonChul-Woo Kim

❮ Previous
Next ❯

Citations

May 3, 2021·The FEBS Journal·Marko AnderluhSandra J van Vliet

❮ Previous
Next ❯

Related Concepts